Neurocarrus

📍 San Francisco, United States🗓 Founded 2015👥 4 employees💰 Last funded Mar 2019

Biotechnology Research 🌐 neurocarrus.com

Neurocarrus is developing a novel therapy to treat pain without addiction. We are a biotechnology company developing a novel drug delivery technology to safely disrupt pain signals without addiction-forming medications or disruption of muscular control. Our first-in-class therapeutic (N-001) is designed to treat the physiological symptoms of pain without invasive surgical procedures or systemically absorbed drugs. We engineered N-001 for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute nerve damage. N-001 is a leading technology in the fight against the prescription opioid abuse and heroin epidemic, which claims the lives of tens of thousands of Americans each year. A safe, non-addictive and effective treatment for pain (a disease burden of over $635 billion in the US*) would have a major impact on human health. Neurocarrus was founded by prominent research scientists in the field of protein engineering. The company is led by a strong management and advisory team with expertise in business, biotechnology and medicine. To date, we have generated extensive in vitro and in vivo data supporting the efficacy of N-001.

Total investors

Early stage

Mid stage

Late stage

2015

Founded